<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37112967</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>17</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Elevated Antibody Titers to Epstein-Barr Virus and Cytomegalovirus in Patients with Drug-Induced Lupus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">986</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15040986</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is an autoimmune disease, which has been associated with Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) infection. Drug-induced lupus (DIL) is a lupus-like disease caused by the intake of therapeutic drugs, which has been estimated to cause approximately 10-15% of lupus-like cases. Although SLE and DIL share common clinical symptoms, there are some fundamental differences between DIL and SLE onset. Moreover, it remains to be examined whether environmental factors, such as EBV and CMV infections, may contribute to the development of DIL. This study focused on examining the possible association between DIL and EBV and CMV infections, by examining IgG titers to EBV and CMV antigens in serum samples by enzyme-linked immunosorbent assays. Antibody titers to EBV early antigen-diffuse and CMV pp52 were found to be significantly elevated in both SLE and DIL patients compared to healthy controls, although no correlation was found for antibodies to the two virus antigens in the respective disease groups. Moreover, total IgG titers were reduced in SLE and DIL serum samples, which may reflect a general lymphocytopenia, which commonly is associated with SLE. The current findings support that EBV and CMV infections may contribute to the development of DIL and that onset of both diseases are related.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trier</LastName><ForeName>Nicole Hartwig</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0003-1548-2009</Identifier><AffiliationInfo><Affiliation>Department of Autoimmunity, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draborg</LastName><ForeName>Anette Holck</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Autoimmunity, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Christoffer Tandrup</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases Rigshospitalet, 2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>S&#xf8;ren</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5654-4993</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf8;jrup</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7838-6180</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houen</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5948-4156</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Autoimmunity, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003586" MajorTopicYN="Y">Cytomegalovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epstein&#x2013;Barr virus</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">cytomegalovirus</Keyword><Keyword MajorTopicYN="N">drug-induced lupus</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>1</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37112967</ArticleId><ArticleId IdType="pmc">PMC10144390</ArticleId><ArticleId IdType="doi">10.3390/v15040986</ArticleId><ArticleId IdType="pii">v15040986</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maple P.A.C. Cytomegalovirus and Epstein&#x2013;Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development. Vaccines. 2020;8:35. doi: 10.3390/vaccines8010035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8010035</ArticleId><ArticleId IdType="pmc">PMC7157723</ArticleId><ArticleId IdType="pubmed">31968673</ArticleId></ArticleIdList></Reference><Reference><Citation>Houen G., Trier N.H. Epstein-Barr Virus and systemic autoimmune diseases. Front. Immunol. 2021;11:587380. doi: 10.3389/fimmu.2020.587380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.587380</ArticleId><ArticleId IdType="pmc">PMC7817975</ArticleId><ArticleId IdType="pubmed">33488588</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein M.A., Achong B.G., Barr Y.M. Virus particles in cultured lymphoblasts from Burkitt&#x2019;s lymphoma. Lancet. 1964;7335:702. doi: 10.1016/S0140-6736(64)91524-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(64)91524-7</ArticleId><ArticleId IdType="pubmed">14107961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkalci D., Jia Y., Winter J.R., Lewis J.E.A., Taylor G.S., Stagg H.R. Risk factor for Epstein-Barr virus-associated cancers a systematic review, critical appraisal and mapping of the epidemiological evidence. J. Glob. Health. 2020;10:010405. doi: 10.7189/jogh.10.010405.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.10.010405</ArticleId><ArticleId IdType="pmc">PMC7125417</ArticleId><ArticleId IdType="pubmed">32257153</ArticleId></ArticleIdList></Reference><Reference><Citation>James J.A., Neas B.R., Moser K.L., Hall T., Bruner G.R., Sestak A.L., Harley J.B. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 2001;44:1122&#x2013;1126. doi: 10.1002/1529-0131(200105)44:5&lt;1122::AID-ANR193&gt;3.0.CO;2-D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200105)44:5&lt;1122::AID-ANR193&gt;3.0.CO;2-D</ArticleId><ArticleId IdType="pubmed">11352244</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Senanayake S., Macaranas I., Albano P.M., Mundo L., Fennell E., Leoncini L., Murray P. MicroRNA and other non-coding RNAs in Epstein-Barr virus-associated cancers. Cancers. 2021;13:3909. doi: 10.3390/cancers13153909.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13153909</ArticleId><ArticleId IdType="pmc">PMC8345394</ArticleId><ArticleId IdType="pubmed">34359809</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A., Izarzugaza J.M.G., Houen G. How compelling are the data for Epstein-Barr virus being a trigger for systemic lupus and other autoimmune diseases? Curr. Opin. Rheumatol. 2016;28:398&#x2013;404. doi: 10.1097/BOR.0000000000000289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000289</ArticleId><ArticleId IdType="pubmed">26986247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A., Munger K.L. EBV and autoimmunity. Curr. Top. Microbiol. Immunol. 2015;390:365&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">26424654</ArticleId></ArticleIdList></Reference><Reference><Citation>Houen G., Trier N.H., Frederiksen J.L. Epstein-Barr Virus and multiple sclerosis. Front. Immunol. 2020;11:587078. doi: 10.3389/fimmu.2020.587078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.587078</ArticleId><ArticleId IdType="pmc">PMC7773893</ArticleId><ArticleId IdType="pubmed">33391262</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostgaard K., Balfour H.H., Jr., Jarret R., Erikstrup C., Pedersen O., Ullum H., Nielsen L.P., Voldstedlund M., Hjalgrim H. Primary Epstein-Barr virus infection with and without infectious mononucleosis. PLoS ONE. 2019;14:e0226436. doi: 10.1371/journal.pone.0226436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0226436</ArticleId><ArticleId IdType="pmc">PMC6917282</ArticleId><ArticleId IdType="pubmed">31846480</ArticleId></ArticleIdList></Reference><Reference><Citation>Trier N.H., Holm B.E., Heiden J., Slot O., Locht H., Lindegaard H., Svendsen A., Nielsen C.T., Jacobsen S., Theander E., et al. Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis. Sci. Rep. 2018;8:3684. doi: 10.1038/s41598-018-22058-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22058-6</ArticleId><ArticleId IdType="pmc">PMC5829227</ArticleId><ArticleId IdType="pubmed">29487382</ArticleId></ArticleIdList></Reference><Reference><Citation>Trier N., Izarzugaza J., Chailyan A., Marcatili P., Houen G. Human MHC-II with Shared Epitope Motifs Are Optimal Epstein-Barr Virus Glycoprotein 42 Ligands&#x2014;Relation to Rheumatoid Arthritis. Int. J. Mol. Sci. 2018;19:317. doi: 10.3390/ijms19010317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19010317</ArticleId><ArticleId IdType="pmc">PMC5796260</ArticleId><ArticleId IdType="pubmed">29361739</ArticleId></ArticleIdList></Reference><Reference><Citation>Wreghitt T.G., Teare E.L., Sule O., Devi R., Rice P. Cytomegalovirus infection in immunocompetent patients. Clin. Infect. Dis. 2003;37:1603&#x2013;1606. doi: 10.1086/379711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/379711</ArticleId><ArticleId IdType="pubmed">14689339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T., Sasaki Y., Maeda T., Komatsu F., Suzuki T., Urita Y. Clinical differentiation of infectious mononucleosis that is caused by Epstein-Barr virus or cytomegalovirus: A single-center case-control study in Japan. J. Infect. Chemother. 2019;25:431&#x2013;436. doi: 10.1016/j.jiac.2019.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2019.01.012</ArticleId><ArticleId IdType="pmc">PMC7128249</ArticleId><ArticleId IdType="pubmed">30773381</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianella S., Massanella M., Wertheim J.O., Smith D.M. The sordid affair between human herpesvirus and HIV. J. Infect. Dis. 2015;212:845&#x2013;852. doi: 10.1093/infdis/jiv148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv148</ArticleId><ArticleId IdType="pmc">PMC4548466</ArticleId><ArticleId IdType="pubmed">25748324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusne S., Shapiro R., Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl. Infect. Dis. 1999;1:187&#x2013;203. doi: 10.1034/j.1399-3062.1999.010307.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-3062.1999.010307.x</ArticleId><ArticleId IdType="pubmed">11428989</ArticleId></ArticleIdList></Reference><Reference><Citation>Limaye A.P., Kirby K.A., Rubenfeld G.D., Leisenring W.M., Bulger E.M., Neff M.J., Gibran N.S., Huang M.L., Santo Hayes T.K., Corey L., et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300:413&#x2013;422. doi: 10.1001/jama.2008.697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2008.697</ArticleId><ArticleId IdType="pmc">PMC2774501</ArticleId><ArticleId IdType="pubmed">18647984</ArticleId></ArticleIdList></Reference><Reference><Citation>Gugliesi F., Pasquero S., Griffante G., Scutera S., Albano C., Pacheco S.F.C., Riva G., Dell&#x2019;Oste V., Biolatti M. Human Cytomegalovirus and Autoimmune Diseases: Where Are We? Viruses. 2021;13:260. doi: 10.3390/v13020260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020260</ArticleId><ArticleId IdType="pmc">PMC7914970</ArticleId><ArticleId IdType="pubmed">33567734</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen N.S., Draborg A.H., Nielsen C.T., Jacobsen S., Houen G. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand. J. Rheumatol. 2015;44:143&#x2013;149. doi: 10.3109/03009742.2014.973061.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2014.973061</ArticleId><ArticleId IdType="pmc">PMC4389709</ArticleId><ArticleId IdType="pubmed">25562120</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanlon P., Avenell A., Aucott L., Vickers M.A. Systematic review and meta-analysis if the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res. Ther. 2014;16:R3. doi: 10.1186/ar4429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4429</ArticleId><ArticleId IdType="pmc">PMC3978841</ArticleId><ArticleId IdType="pubmed">24387619</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey S., Rodrigues C., Nikam C., Samant R. A study of CMV infection in SLE patients. Indian. J. Rheumatol. 2014;9((Suppl. 1)):S33. doi: 10.1016/j.injr.2014.10.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injr.2014.10.092</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C., Gershwin M.E. Drug-induced lupus erythematosus: Incidence, management and prevention. Drug Saf. 2011;34:357&#x2013;374. doi: 10.2165/11588500-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11588500-000000000-00000</ArticleId><ArticleId IdType="pubmed">21513360</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh M.F., Jordan N., D&#x2019;Cruz D.P. Systemic lupus erythematosus. Clin. Med. 2017;17:78&#x2013;83. doi: 10.7861/clinmedicine.17-1-78.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.17-1-78</ArticleId><ArticleId IdType="pmc">PMC6297589</ArticleId><ArticleId IdType="pubmed">28148586</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Sawalha A.H. Drug-induced lupus erythematosus: An update on drugs and mechanisms. Curr. Opin. Rheumatol. 2018;30:490&#x2013;497. doi: 10.1097/BOR.0000000000000522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000522</ArticleId><ArticleId IdType="pmc">PMC7299070</ArticleId><ArticleId IdType="pubmed">29870500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R.L. Drug-induced lupus. Toxicology. 2005;209:135&#x2013;147. doi: 10.1016/j.tox.2004.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2004.12.025</ArticleId><ArticleId IdType="pubmed">15767026</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R.L. Drug-induced lupus. Expert. Opin. Drug Saf. 2015;14:361&#x2013;378. doi: 10.1517/14740338.2015.995089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.2015.995089</ArticleId><ArticleId IdType="pubmed">25554102</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt D.J., Waldron J.M. Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy. J. Am. Med. Assoc. 1954;155:1491&#x2013;1492. doi: 10.1001/jama.1954.73690350001010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1954.73690350001010</ArticleId><ArticleId IdType="pubmed">13183772</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojinca V.C., Bojinca M., Gheorghe M., Birceanu A., Iosif C.I., Balanescu S.M., Balanescu A.R. Stevens-Johnsons syndrome or drug-induced lupus&#x2014;A clinical dilemma: A case report and review of the literature. Biomed. Rep. 2018;9:37&#x2013;41. doi: 10.3892/br.2018.1098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2018.1098</ArticleId><ArticleId IdType="pmc">PMC6007037</ArticleId><ArticleId IdType="pubmed">29930803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ara&#xfa;jo-Fern&#xe1;ndez S., Ahij&#xf3;n-Lana M., Isenberg D.A. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. Lupus. 2014;23:545&#x2013;553. doi: 10.1177/0961203314523871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314523871</ArticleId><ArticleId IdType="pubmed">24557776</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlienger R.G., Bircher A.J., Meier C.R. Minocycline-induced lupus. A systematic review. Dermatology. 2000;200:223&#x2013;231. doi: 10.1159/000018387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000018387</ArticleId><ArticleId IdType="pubmed">10828631</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky D.S. Anti-DNA and autoantibodies. Curr. Opin. Rheumatol. 2000;12:364&#x2013;368. doi: 10.1097/00002281-200009000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002281-200009000-00002</ArticleId><ArticleId IdType="pubmed">10990170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly A.S., De la Harpe Golden P., D&#x2019;Arcy C., Lally A. Drug-induced lupus erythematosus secondary to pirfenidone. Br. J. Dermatol. 2018;178:1437&#x2013;1438. doi: 10.1111/bjd.16246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.16246</ArticleId><ArticleId IdType="pubmed">29266198</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall J.L. Identifying drug-induced lupus. Neurol. USA Pharm. 2011;1:37.</Citation></Reference><Reference><Citation>Sarkar R., Paul R., Pandey R., Roy D., Sau T.J., Mani A., Ruia A.V., Mondal J. Drug-induced Lupus Presenting with Myocarditis. J. Assoc. Physicians India. 2017;65:110.</Citation><ArticleIdList><ArticleId IdType="pubmed">28782328</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasoo S. Drug-induced lupus: An update. Lupus. 2006;15:757&#x2013;761. doi: 10.1177/0961203306070000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306070000</ArticleId><ArticleId IdType="pubmed">17153847</ArticleId></ArticleIdList></Reference><Reference><Citation>Batchelor R.J., Welsh K.I., Tinoco R.M., Dollery C.T., Hughes G.R., Bernstein R., Ryan P., Naish P.F., Aber G.M., Bing R.F., et al. Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility. Lancet. 1980;1:1107&#x2013;1109. doi: 10.1016/S0140-6736(80)91554-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(80)91554-8</ArticleId><ArticleId IdType="pubmed">6103441</ArticleId></ArticleIdList></Reference><Reference><Citation>Speirs C., Fielder A.H., Chapel H., Davey N.J., Batchelor J.R. Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet. 1989;1:922&#x2013;924. doi: 10.1016/S0140-6736(89)92506-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(89)92506-3</ArticleId><ArticleId IdType="pubmed">2565418</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson I., Nordmark B., Hassan Bakri A., Gr&#xf6;ndal G., Larsson P., Forslid J., Klareskog L., Ringertz B. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology. 2000;39:886&#x2013;893. doi: 10.1093/rheumatology/39.8.886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/39.8.886</ArticleId><ArticleId IdType="pubmed">10952745</ArticleId></ArticleIdList></Reference><Reference><Citation>Laursen I.A., Blou L., Sullivan J.S., Bang P., Balstrup F., Houen G. Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma. Transfus. Med. Hemother. 2014;41:205&#x2013;212. doi: 10.1159/000357982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000357982</ArticleId><ArticleId IdType="pmc">PMC4086766</ArticleId><ArticleId IdType="pubmed">25053934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobhy N., Niazy M.H., Kama A. Lymphopenia in systemic lupus erythematosus patients: Is it more than a laboratory finding? Egypt. Rheumatol. 2020;42:23&#x2013;26. doi: 10.1016/j.ejr.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejr.2019.04.003</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nz C. Cytotoxicity in Epstein Barr virus specific immune control. Curr. Opin. Virol. 2021;46:1&#x2013;8. doi: 10.1016/j.coviro.2020.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2020.07.011</ArticleId><ArticleId IdType="pubmed">32771660</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen M., Sauce D., Deback C., Arnaud L., Mathian A., Miyara M., Boutolleau D., Parizot C., Dorgham K., Papagno L., et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog. 2011;7:e1002328. doi: 10.1371/journal.ppat.1002328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002328</ArticleId><ArticleId IdType="pmc">PMC3197610</ArticleId><ArticleId IdType="pubmed">22028659</ArticleId></ArticleIdList></Reference><Reference><Citation>Doaty S., Agrawal H., Bauer E., Furst D.E. Infection and Lupus: Which Causes Which? Curr. Rheumatol. Rep. 2016;18:13. doi: 10.1007/s11926-016-0561-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-016-0561-4</ArticleId><ArticleId IdType="pubmed">26951251</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A.H., Duus K., Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin. Dev. Immunol. 2013;2013:535738. doi: 10.1155/2013/535738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/535738</ArticleId><ArticleId IdType="pmc">PMC3766599</ArticleId><ArticleId IdType="pubmed">24062777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos G.C., Magrath I.T., Balow J.E. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J. Immunol. 1983;131:1797&#x2013;1801. doi: 10.4049/jimmunol.131.4.1797.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.131.4.1797</ArticleId><ArticleId IdType="pubmed">6311898</ArticleId></ArticleIdList></Reference><Reference><Citation>Berner B.R., Tary-Lehmann M., Yonkers N.L., Askari A.D., Lehmann P.V., Anthony D.D. Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell. Immunol. 2005;235:29&#x2013;38. doi: 10.1016/j.cellimm.2005.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2005.06.010</ArticleId><ArticleId IdType="pubmed">16181618</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorley-Lawson D.A. Epstein-Barr virus: Exploiting the immune system. Nat. Rev. Immunol. 2001;1:75&#x2013;82. doi: 10.1038/35095584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35095584</ArticleId><ArticleId IdType="pubmed">11905817</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson S., Huen D., Rove M., Dawson C., Johnson G., Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl. Acad. Sci. USA. 1993;90:8479&#x2013;8483. doi: 10.1073/pnas.90.18.8479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.18.8479</ArticleId><ArticleId IdType="pmc">PMC47380</ArticleId><ArticleId IdType="pubmed">8397406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wucherpfennig K.W. Mechanisms for the induction of autoimmunity by infectious agents. J. Clin. Investig. 2001;108:1097&#x2013;1104. doi: 10.1172/JCI200114235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200114235</ArticleId><ArticleId IdType="pmc">PMC209539</ArticleId><ArticleId IdType="pubmed">11602615</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>